These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 20488431

  • 1. Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.
    Macejko TT, Bergmann MT, Williams JI, Gow JA, Gomes PJ, McNamara TR, Abelson MB, Bepotastine Besilate Ophthalmic Solutions Clinical Study Group.
    Am J Ophthalmol; 2010 Jul; 150(1):122-127.e5. PubMed ID: 20488431
    [Abstract] [Full Text] [Related]

  • 2. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB, Torkildsen GL, Williams JI, Gow JA, Gomes PJ, McNamara TR, Bepotastine Besilate Ophthalmic Solutions Clinical Study Group.
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [Abstract] [Full Text] [Related]

  • 3. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
    Williams JI, Kennedy KS, Gow JA, Torkildsen GL, Abelson MB, Gomes PJ, McNamara TR, Bepotastine Besilate Ophthalmic Solutions Study Group.
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):385-93. PubMed ID: 21649522
    [Abstract] [Full Text] [Related]

  • 4. Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge.
    Torkildsen GL, Williams JI, Gow JA, Gomes PJ, Abelson MB, McNamara TR, Bepotastine Besilate Ophthalmic Solutions Clinical Study Group.
    Ann Allergy Asthma Immunol; 2010 Jul; 105(1):57-64. PubMed ID: 20642205
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
    Mah FS, Rosenwasser LJ, Townsend WD, Greiner JV, Bensch G.
    Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
    [Abstract] [Full Text] [Related]

  • 6. Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis.
    Meier EJ, Torkildsen GL, Gow JA, McNamara TR, Gomes PJ, Williams JI, Bepotastine Besilate Ophthalmic Solutions Study Group.
    Allergy Asthma Proc; 2012 Jun; 33(3):265-74. PubMed ID: 22991696
    [Abstract] [Full Text] [Related]

  • 7. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
    Greiner JV, Udell IJ.
    Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population.
    Abelson MB, Ferzola NJ, McWhirter CL, Crampton HJ.
    Pediatr Allergy Immunol; 2004 Dec; 15(6):551-7. PubMed ID: 15610370
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
    Fujishima H, Ohashi Y, Takamura E.
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.
    Abelson MB, Spangler DL, Epstein AB, Mah FS, Crampton HJ.
    Curr Eye Res; 2007 Dec; 32(12):1017-22. PubMed ID: 18085465
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model.
    Abelson MB, Chapin MJ, Kapik BM, Shams NB.
    Arch Ophthalmol; 2003 May; 121(5):626-30. PubMed ID: 12742839
    [Abstract] [Full Text] [Related]

  • 15. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
    Crampton HJ.
    Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model.
    Brodsky M, Berger WE, Butrus S, Epstein AB, Irkec M.
    Eye Contact Lens; 2003 Apr; 29(2):113-6. PubMed ID: 12695716
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: a single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis.
    Torkildsen GL, Abelson MB, Gomes PJ.
    Clin Ther; 2008 Jul; 30(7):1272-82. PubMed ID: 18691986
    [Abstract] [Full Text] [Related]

  • 20. [Safety and efficacy of a new preservative-free levocabastine ophthalmic solution (Levofree®) using the conjunctival provocation test].
    Allaire C, Siou-Mermet R, Bassols A.
    J Fr Ophtalmol; 2012 Sep; 35(7):491-8. PubMed ID: 22498504
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.